Merck (MRK) stock price rises as Enflonsia approval and insider filing keep attention on what’s next
New York, February 6, 2026, 11:57 EST — Regular session
- Merck shares rose nearly 2% in midday trade, extending a multi-day climb.
- Health Canada cleared Merck’s RSV preventive ENFLONSIA for newborns and infants.
- Investors are watching an FDA action date later this month tied to Keytruda.
Merck & Co. shares rose 1.8% to $121.92 on Friday, after trading as high as $122.65 earlier in the session. The stock had opened at $121.01.
The move came with a broad rebound across U.S. equities and healthcare, a pocket that tends to draw bids when risk appetite gets shaky. The SPDR S&P 500 ETF gained about 1.5% and the Health Care Select Sector SPDR was up about the same in midday trading.
Merck’s shares were also…
